Plasma Indoxyl sulfate and estimated Glomerular filtration rate - Association with long-term clinical outcome in patients with coronary artery disease-

Circulation Journal

Volumn 78, Issue 10, 2014, Pages 2477-2482

  Yoshikawa, Daiji ^a,c   Ishii, Hideki ^a   Suzuki, Susumu ^a   Takeshita, Kyosuke ^b   Kumagai, Soichiro ^d   Hayashi, Mutsuharu ^a,c   Niwa, Toshimitsu ^a   Izawa, Hideo ^c   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c FUJITA HEALTH UNIVERSITY BANTANE HOSPITAL   (Japan)

^d AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cardio renal syndrome; Chronic kidney disease; Uremic toxin

Indexed keywords

INDICAN;

AGED; ARTICLE; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RISK ASSESSMENT; SURVIVAL RATE; BLOOD; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INDICAN; MALE; MIDDLE AGED; SURVIVAL RATE; TIME FACTORS;

EID: 84908236178     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0401     Document Type: Article

References (37)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100.
3. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn study. Kidney Int 2002; 62: 1402-1407.
4. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al; American Heart Association Councils on Kidney in Cardiovascular Disease HBPRCC, Epidemiology, Prevention. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003; 108: 2154-2169.
5. Schrier RW. Cardiorenal versus renocardiac syndrome: Is there a difference? Nephrology 2007; 3: 637.
6. Ronco C. Cardiorenal and renocardiac syndromes: Clinical disorders in search of a systematic definition. Int J Artif Organs 2008; 31: 1-2.
7. Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H. Cardiorenal syndrome: The emerging role of protein-bound uremic toxins. Circ Res 2012; 111: 1470-1483.
8. Rubenstein MH, Harrell LC, Sheynberg BV, Schunkert H, Bazari H, Palacios IF. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000; 102: 2966-2972.
9. Kaya E, Cuneo A, Hochadel M, Junger C, Stepper W, Bramlage P, et al. Impact of chronic kidney disease on the prognosis of patients undergoing percutaneous coronary interventions using drug-eluting stents. Clin Res Cardiol 2011; 100: 1103-1109.
10. Niwa T. Uremic toxicity of indoxyl sulfate. Nagoya J Med Sci 2010; 72: 1-11.
11. Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994; 124: 96-104.
12. Niwa T, Ise M, Miyazaki T. Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 1994; 14: 207-212.
13. Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010; 31: 1771-1779.
14. Lekawanvijit S, Kompa AR, Manabe M, Wang BH, Langham RG, Nishijima F, et al. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PloS One 2012; 7: 41281, doi:10.1371/journal.pone.0041281.
15. Sato B, Yoshikawa D, Ishii H, Kikuchi R, Arima T, Takeshita K, et al. Indoxyl sulfate, a uremic toxin, and carotid intima-media thickness in patients with coronary artery disease. Int J Cardiol 2013; 163: 214-216.
16. Sato B, Yoshikawa D, Ishii H, Suzuki S, Inoue Y, Takeshita K, et al. Relation of plasma indoxyl sulfate levels and estimated glomerular filtration rate to left ventricular diastolic dysfunction. Am J Cardiol 2013; 111: 712-716.
17. Watanabe I, Tatebe J, Namba S, Koizumi M, Yamazaki J, Morita T. Activation of aryl hydrocarbon receptor mediates indoxyl sulfateinduced monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells. Circ J 2013; 77: 224-230.
18. Adelibieke Y, Shimizu H, Saito S, Mironova R, Niwa T. Indoxyl sulfate counteracts endothelial effects of erythropoietin through suppression of AKT phosphorylation. Circ J 2013; 77: 1326-1336.
19. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings: TIMI Study Group. N Engl J Med 1985; 312: 932-936.
20. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 52: e1-e142, doi:10.1016/j.jacc.2008.05.007.
21. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
22. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: A KDIGO controversies conference report. Kidney Int 2011; 80: 17-28.
23. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539-2550.
24. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22: 107-133.
25. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442-451.
26. Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 2007; 5: 1302-1308.
27. Yamamoto H, Tsuruoka S, Ioka T, Ando H, Ito C, Akimoto T, et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 2006; 69: 1780-1785.
28. Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol 2007; 27: 30-35.
29. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 825-831.
30. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: Effects on the cardiovascular system. Circulation 2007; 116: 85-97.
31. Enomoto A, Takeda M, Tojo A, Sekine T, Cha SH, Khamdang S, et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 2002; 13: 1711-1720.
32. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al; European Uremic Toxin Work Group. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 1551-1558.
33. Shimazu S, Hirashiki A, Okumura T, Yamada T, Okamoto R, Shinoda N, et al. Association between indoxyl sulfate and cardiac dysfunction and prognosis in patients with dilated cardiomyopathy. Circ J 2013; 77: 390-396.
34. Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N. A multicenter, randomized, double-blind, placebo-controlled, doseranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006; 47: 565-577.
35. Shibahara H, Shibahara N. Cardiorenal protective effect of the oral uremic toxin absorbent AST-120 in chronic heart disease patients with moderate CKD. J Nephrol 2010; 23: 535-540.
36. Nakai K, Fujii H, Kono K, Goto S, Fukagawa M, Nishi S. Effects of AST-120 on left ventricular mass in predialysis patients. Am J Nephrol 2011; 33: 218-223.
37. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: An oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl 1997; 62: S23-S28.